Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids)
Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169)
12/2002
12/19/2002WO2002100879A1 Novel anti-inflammatory 17.alpha.-heterocyclic-esters of 17.beta.carbothioate androstane derivatives
12/19/2002WO2002100859A1 Pde iv inhibitors
12/19/2002WO2002100854A1 Lactone formulations and method of use
12/19/2002WO2002100849A2 Novel nitriles useful as reversible inhibitors of cysteine proteases
12/19/2002WO2002100833A1 Rho KINASE INHIBITORS
12/19/2002WO2002100830A1 Pyrrolidine derivatives as factor xa inhibitors
12/19/2002WO2002100826A2 Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs
12/19/2002WO2002100824A1 A novel alkaloid derivative and a pharmaceutical composition containing the same
12/19/2002WO2002100812A1 Carboxylic acid derivative and salt thereof
12/19/2002WO2002100486A1 Method and apparatus for treating uterine myoma
12/19/2002WO2002100456A1 Using supercritical fluids to infuse therapeutic on a medical device
12/19/2002WO2002100445A1 Treatment and composition for wound healing
12/19/2002WO2002100437A2 Ophthalmic compositions comprising hyaluronic acid
12/19/2002WO2002100433A1 Medicinal compositions
12/19/2002WO2002100429A1 Combination therapies using vitamin b12 and interferon for treatment of viral, proliferative and inflammatory diseases
12/19/2002WO2002100428A1 Combination therapies using vitamin b12 and therapeutic agents for treatment of viral, proliferative and inflammatory diseases
12/19/2002WO2002100412A2 Stabilized dispersion of phytosterol in oil
12/19/2002WO2002100409A1 Antiinflammatoric and antitussive compositions
12/19/2002WO2002100408A2 Treating neuropathic/inflammatory pain by targeting a composition (e.g. zd7288) to hcn pacemaker channels
12/19/2002WO2002100405A1 Isoquinoline inhibitors of p38
12/19/2002WO2002100391A1 Swallow tablet comprising paracetamol
12/19/2002WO2002100385A1 Crude drug patch
12/19/2002WO2002100373A1 Skin preparation
12/19/2002WO2002100354A2 Pyrrolo[2,3-d]pyrimidine nucleoside analogs
12/19/2002WO2002100351A2 A method for treating inflammatory diseases by administering a ppar-delta agonist
12/19/2002WO2002100344A2 Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
12/19/2002WO2002100332A2 Isoxazoline compounds having mif antagonist activity
12/19/2002WO2002100330A2 METHODS OF ADMINISTERING ANTI-TNFα ANTIBODIES
12/19/2002WO2002100328A2 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels
12/19/2002WO2002100327A2 Substituted 1-benzazepines and derivatives thereof
12/19/2002WO2002100325A2 Polyvalent nanoparticles
12/19/2002WO2002085937A3 Inflammation-specific peptides and the uses thereof
12/19/2002WO2002085906A3 Phthalazinones derivatives useful as pde4/7 inhibitors
12/19/2002WO2002085327A3 Use of nsaids for prevention and treatment of cellular abnormalities of the female reproductive tract
12/19/2002WO2002078684A3 Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders
12/19/2002WO2002070561A3 Nuclear hormone receptor ligand binding domain
12/19/2002WO2002070560A3 Nuclear hormone receptor ligand binding domain
12/19/2002WO2002070558A3 Nuclear hormone receptor ligand binding domain
12/19/2002WO2002066624A3 Novel human protease and polynucleotides encoding the same
12/19/2002WO2002064755A3 Post-partum mammalian placenta, its use and placental stem cells therefrom
12/19/2002WO2002062797A3 Pharmaceutical uses and synthesis of diketopiperazines
12/19/2002WO2002060894A3 Sulfonamide lactam inhibitors of factor xa
12/19/2002WO2002058681A3 Use of rhein for preparing a medicine for treating a high level of il-1
12/19/2002WO2002056878A3 Pharmaceutical composition having reduced tendency for drug crystallization
12/19/2002WO2002055501A3 N-pyridyl carboxamide derivatives and pharmaceutical compositions containing them
12/19/2002WO2002045723A9 Inflammatory cytokine secretion inhibition with modified mammalian blood
12/19/2002WO2002042248A3 Naphthalene derivatives
12/19/2002WO2002024727A3 New inhibitors of iapp fibril formation and uses thereof
12/19/2002WO2002012338A3 Screening method
12/19/2002WO2001077169A9 Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
12/19/2002WO2001068859A9 Il-17 receptor like molecules and uses thereof
12/19/2002WO2001068679A9 Peptides targeting specifically tumor-derived endothelial cells
12/19/2002US20020193612 Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes
12/19/2002US20020193605 Selectively inhibits action of N-type calcium channel; treatment of ischemic cerebrovascular disorders caused by cerebral infarction or intracerebral bleeding, Alzheimer's disease, AIDS related dementia, Parkinson's disease
12/19/2002US20020193446 Compounds and methods for the inhibition of the expression of VCAM-1
12/19/2002US20020193439 90-95% eicosapentaenoic acid (EPA) and < 5% of docosahexaenoic acid (DHA); treating psychiatric or central nervous disorders
12/19/2002US20020193432 Useful as modulators of the interaction between the receptor for advanced glycated end product and its ligands
12/19/2002US20020193414 Adamantane derivatives
12/19/2002US20020193409 Prodrugs of anticancer agents employing substituted aromatic acids
12/19/2002US20020193405 For prophylaxis and therapy of diseases, such as cell proliferation or apoptosis mediated diseases
12/19/2002US20020193396 Sulfonamido ether substituted imidazoquinolines
12/19/2002US20020193390 Pharmaceutical compositions containing an N-(substituted glycyl)-2- cyanopyrrolidine and at least one other antidiabetic agent and their use in inhibiting dipeptidyl peptidase-IV
12/19/2002US20020193377 Quinazolines as MMP-13 inhibitors
12/19/2002US20020193357 Liver X receptor agonists
12/19/2002US20020192800 Nucleotide sequences coding polypeptide for use in the prevention, diagnosis and treatment of thrombosis, emphysema and liver disorders
12/19/2002US20020192758 C3b/C4b complement receptor-like molecules and uses thereof
12/19/2002US20020192749 Human polynucleotides, polypeptides, and antibodies
12/19/2002US20020192682 Polynucleotides and polypeptides of the IFNalpha-2 gene
12/19/2002US20020192647 Diagnostic method
12/19/2002US20020192643 Nucleotide sequences coding polypeptide for use in the treatment of cell proliferation or inflammatory disorders
12/19/2002US20020192305 Inflammatory mediation obtained from atractylodes lancea
12/19/2002US20020192288 Methods and compositions for treating pain of the mucous membrane
12/19/2002US20020192285 Controlled release pellet formulation
12/19/2002US20020192282 Multilayer pharmaceutical product for release in the colon
12/19/2002US20020192280 Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents
12/19/2002US20020192276 Use of G class immunoglobulins for the topical treatment of atopic dermatitis
12/19/2002US20020192216 Therapeutic use
12/19/2002US20020192161 Animal model for evaluating analgesics
12/19/2002US20020192157 Treatment and diagnosis of macrophage mediated disease
12/19/2002CA2487039A1 Combination therapies using vitamin b12 and interferon for treatment of viral, proliferative and inflammatory diseases
12/19/2002CA2487038A1 Combination therapies using vitamin b12 and therapeutic agents for treatment of viral, proliferative and inflammatory diseases
12/19/2002CA2450472A1 Screening method using bnpi and dnpi
12/19/2002CA2450400A1 Medicinal compositions
12/19/2002CA2450240A1 Treatment and composition for wound healing
12/19/2002CA2450027A1 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels
12/19/2002CA2449934A1 Treating pain by targeting hyperpolarization-activated, cyclic nucleotide-gated channels
12/19/2002CA2449629A1 Pyrrolidine derivatives as factor xa inhibitors
12/19/2002CA2449544A1 Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs
12/19/2002CA2449272A1 Intracellular signaling molecules
12/19/2002CA2449247A1 A method for treating inflammatory diseases by administering a ppar-delta agonist
12/19/2002CA2449213A1 Ophthalmic compositions comprising hyaluronic acid
12/19/2002CA2447687A1 Substituted 1-benzazepines and derivatives thereof
12/19/2002CA2447557A1 Using supercritical fluids to infuse therapeutic on a medical device
12/19/2002CA2446223A1 Stabilized dispersion of phytosterol in oil
12/18/2002EP1266899A2 Rapamycin hdroxyesters, process for their preparation and pharmaceutical compositions containing them
12/18/2002EP1266663A1 Eosinophil-specific apoptosis inducer
12/18/2002EP1266224A1 Modulation of histone deacetylase
12/18/2002EP1266014A2 Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
12/18/2002EP1266012A2 Proteases
12/18/2002EP1266002A2 Il-17 receptor like molecules and uses thereof
1 ... 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 ... 1272